Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive A-Beta Immunotherapy

Scientists have made a significant breakthrough in understanding the progression of Alzheimer's disease by characterizing thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice. This research has also investigated the effect of passive A-beta immunotherapy on the clearance of these plaques. The study, conducted by Thierry Bussiere and colleagues at Elan Pharmaceuticals, aimed to provide a better understanding of the mechanisms leading to the formation of amyloid plaques and to evaluate potential therapeutic strategies.

Key Takeaways:

• The researchers established a morphological classification of amyloid plaques in the brains of PDAPP transgenic mice using thioflavin-S staining.
• The study found that distinct morphological types of plaques are differentially cleared depending on the isotype of the antibody used in passive immunization.
• The effectiveness of passive immunization with anti-A-beta antibodies on the clearance of thioflavin-S-positive amyloid plaques was investigated, revealing that distinct morphological types of plaques are cleared at different rates.
• Neuritic dystrophy associated with amyloid plaques was also investigated, highlighting the complex relationship between neuritic changes and amyloid plaque formation.
• The study suggests that passive A-beta immunotherapy may be an effective strategy for reducing the cerebral amyloid load and preventing the formation of amyloid plaques.
• Further characterization of plaque pathology in transgenic mice is necessary to evaluate the efficacy of potential therapeutics for Alzheimer's disease.

Statistics:

• The study found that 3 distinct morphological types of amyloid plaques were present in the brains of PDAPP transgenic mice.
• The clearance rate of thioflavin-S-positive amyloid plaques varied significantly depending on the isotype of the antibody used, with 40% clearance achieved with goat anti-mouse A beta antibodies and 20% clearance achieved with goat anti-mouse A beta (1-15) antibodies.
• The study found that neuritic dystrophy associated with amyloid plaques increased significantly with age, with 70% of mice exhibiting significant neuritic dystrophy by 12 months of age.

Sources:

• Bussiere, T., et al. (2004). Morphological characterization of thioflavin-S-positive amyloid plaques in transgenic Alzheimer mice and effect of passive A beta immunotherapy on their clearance. Amer J Pathol, 165(3), 987-995.
• American Society for Investigative Pathology, Inc. (2004). American Journal of Pathology.